Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Uranium Energy ( AMEX:UEC ) , Arcus Biosciences ( NYSE:RCUS )
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, "I like nuclear." Supporting his view, HC Wainwright & Co. analyst Heiko F. Ihle, on Aug. 6, maintained Uranium Energy with a Buy and raised the price target from $12.25 to $12.75.
Why Is Gilead Sciences Stock Surging Friday? - Gilead Sciences ( NASDAQ:GILD )
Q2 adjusted EPS of $2.01 beat the $1.94 consensus; revenue hit $7.08 billion vs. $6.94 billion estimate. Biktarvy sales rose 9% to $3.5 billion; Descovy surged 35% to $653 million amid higher demand and pricing. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session ...
Arcus ( RCUS ) Q2 Revenue Jumps 310%
Arcus Biosciences ( NYSE:RCUS ) , a clinical-stage biotech focused on cancer immunotherapies, reported its second-quarter 2025 earnings on August 6, 2025. GAAP revenue and earnings per share both surpassed Wall Street expectations by a wide margin, with reported GAAP revenue at $160 million ...
Arcus Biosciences, Inc. ( RCUS ) Reports Break-Even Earnings for Q2
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Pacira ( PCRX ) Tops Q2 Earnings Estimates
Pacira (PCRX) delivered earnings and revenue surprises of +2.78% and -1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. ( RCUS ) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Castle Biosciences ( NASDAQ:CSTL ) , EverQuote ( NASDAQ:EVER )
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results and issued second-quarter guidance ...
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - BloomZ ( NASDAQ:BLMZ ) , AIFU ( NASDAQ:AIFU )
Shares of ThredUp Inc. TDUP rose sharply in today's pre-market trading after the company announced better-than-expected first-quarter results and raised its FY25 sales forecast. ThredUp posted a quarterly loss of 4 cents per share, compared to market estimates for a loss of 7 cents per share.
Arcus Biosciences, Inc. ( RCUS ) Reports Q4 Loss, Tops Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 11.97% and 9.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Telefonaktiebolaget L M ( NASDAQ:ERIC ) , Acacia Research ( NASDAQ:ACTG )
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Friday. Shares of Telefonaktiebolaget LM Ericsson ERIC fell sharply in today's pre-market trading after the company reported fourth-quarter fiscal 2024 results on Friday.
Moderna ( MRNA ) Stock Jumps 11.7%: Will It Continue to Soar?
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arcus Biosciences, Inc. ( RCUS ) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 6.54% and 43.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Regeneron ( REGN ) Tops Q3 Earnings and Revenue Estimates
Regeneron (REGN) delivered earnings and revenue surprises of 6.04% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Arcus Biosciences, Inc. ( RCUS ) to Report a Decline in Earnings: What to Look Out for
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis ( EXEL ) Q3 Earnings and Revenues Beat Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 11.90% and 9.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Attovia Therapeutics Appoints Chief Financial Officer - Connect Biopharma Hldgs ( NASDAQ:CNTB )
FREMONT, Calif., Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer.
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Abbott Laboratories ( NYSE:ABT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer analyst Suraj Kalia initiated coverage on Abbott Laboratories ABT with an Outperform rating and ...
Gilead ( GILD ) Gains 16.8% in 3 Months: How Should You Play the Stock?
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Arcus Biosciences, Inc. ( RCUS ) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 0% and 26.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. ( JANX ) Reports Q2 Loss, Tops Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of 65.63% and 1,078.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. ( CLSD ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. ( RCUS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
SAN MATEO, Calif., Aug. 01, 2024 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( Sagimet, Nasdaq: SGMT ) , a clinical-stage biopharmaceutical company developing novel fatty acid synthase ( FASN ) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the ...
Is The Options Market Predicting a Spike In Arcus Biosciences ( RCUS ) Stock?
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
Gilead ( GILD ) , RCUS Announce Data From Colorectal Cancer Study
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies Why Is Arcus Biosciences Stock Trading Higher Today? - Arcus Biosciences ( NYSE:RCUS ) , Gilead Sciences ( NASDAQ:GILD )
On Saturday, Gilead Sciences Inc GILD and Arcus Biosciences Inc RCUS released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study.
Arcus Biosciences, Inc. ( RCUS ) Reports Q1 Loss, Tops Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Adverum Biotechnologies ( ADVM ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcus Biosciences, Inc. ( RCUS ) Report Negative Earnings Next Week? What You Should Know
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks Generating Improved Relative Strength: Arcus Biosciences
Arcus Biosciences ( RCUS ) had its Relative Strength ( RS ) Rating upgraded from 70 to 73 Tuesday -- a welcome improvement, but still below the 80 or higher score you prefer to see. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
Wall Street Analysts Think Arcus Biosciences, Inc. ( RCUS ) Could Surge 151.61%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
C4 Therapeutics ( CCCC ) to Report Q4 Earnings: What's in Store?
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
INCY: Elite 4 Biotech Stocks to Buy Now for Explosive Returns
The biotech industry's long-term outlook looks robust, driven by the growing need for personalized treatment options, rapid adoption of agricultural biotechnology to increase the productivity of crops, ongoing technological breakthroughs and innovation, and favorable government policies.
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.
Exelixis ( EXEL ) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - Peoples Financial ( OTC:PFBX ) , Amrep ( NYSE:AXR )
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Bitcoin, Ethereum, Dogecoin Rise As Crypto Shorts Face Liquidations?; Meta Gets 22% Price Target Boost Ahead Of Q4 Results As Analyst Pins Hopes On Ad Market Recovery, Reels Strength - Top Headlines Today While US Was Sleeping
Floki Tackles Regulatory Concerns In Hong Kong, Implements High-Yield Staking Program Safeguards 'Dogecoin Killer' Shiba Inu Burn Rate Skyrockets Over 1,500% On New Plan To Integrate 1000 New Projects To Shibarium Neuralink-Inspired Token Soars 3400% After Elon Musk Announces First Human Implant
Why Is Arcus Biosciences Stock Trading Higher Today? - Arcus Biosciences ( NYSE:RCUS ) , Gilead Sciences ( NASDAQ:GILD )
Arcus Biosciences Inc RCUS shares are trading higher after Gilead Sciences Inc GILD amended their collaboration agreement and announced a separate equity investment of $320 million in Arcus stock at $21.00 per share.
Microsoft, UPS, GM, Pfizer, Super Micro Computer, Calix, Sanmina, and More Stock Market Movers
Microsoft, Alphabet, Super Micro Computer, Calix, Sanmina, and More Market Movers ...
Biotech Stocks in Focus: ( NYSE: RCUS ) ( NASDAQ: HUMA ) ( CSE: BHSC )
Biotech Stocks in Focus: ( NYSE: RCUS ) ( NASDAQ: HUMA ...
Exelixis ( EXEL ) Outperforms on Cabometyx and Pipeline Progress
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Taiho Ventures Expands Investment Pool to $400 Million to Continue Quality Investments and Accelerate Open ... - PR Newswire
Taiho Ventures Expands Investment Pool to $400 Million to Continue Quality Investments and Accelerate Open ... PR ...
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
Pharma Co.'s Partnership a Key Validation
December 5, 2023 ( Investorideas.com Newswire ) Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
Exelixis ( EXEL ) Collaborates With Arcus for Kidney Cancer Study
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period ( 2019-2032 ) | DelveInsight
Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with others, there are several emerging key players, that are expected to change the dynamics of the metastatic colorectal cancer market in the coming years owing to the positive outcomes of the ...
It's Small Stocks' Time To Rally - Analysts Like These 11 Best
It's been all about the biggest of the big S&P 500 stocks all year. But now, investors are starting to look for big gains from small stocks.
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity - Arcus Biosciences ( NYSE:RCUS ) , Gilead Sciences ( NASDAQ:GILD )
Gilead Sciences Inc GILD and Arcus Biosciences Inc RCUS announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate ( ORR ) and six-month progression-free survival ( PFS ) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.
Arcus Biosciences, Inc. ( RCUS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks That Hit 52-Week Lows On Thursday - PRA Group ( NASDAQ:PRAA ) , Perimeter Solutions ( NYSE:PRM )
On Thursday, 369 companies hit new 52-week lows. The largest company in terms of market cap to set a new 52-week low was Coca-Cola KO. The smallest company by market cap to hit a new 52-week low was Neptune Wellness Solns NEPT.
